ArticleOpen veterinary journal2025
Astaxanthin improves hematology, interleukin-6, and tumor necrosis factor-α in the albino rats' kidney model of dexamethasone toxicity.
Article in Open veterinary journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Effects of nano-formulated tenoxicam on pancreatic alterations in dexamethasone-induced metabolic syndrome in rats.Naunyn-Schmiedeberg's archives of pharmacology · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: In therapeutic scenarios, the anti-inflammatory medication dexamethasone is frequently administered. However, the consequences of prolonged use and dose residue may result in dexamethasone toxicity. Astaxanthin is a carotenoid antioxidant that may lessen the harmful effects of dexamethasone. Aim: This study aimed to investigate the efficacy of astaxanthin in a dexamethasone toxicity model in the kidney of albino rats based on hematological profiles and interleukin-6 (IL-6) and tumor necrosis factor-alpha (TNF-α) expression. Methods: The study involved the random assignment of 25 albino rats into five treatment groups with five replications: (C-) placebo, (C+) intramuscular injection of 0.75 mg/kg BW of dexamethasone, and (T1, T2, and T3) intramuscular injection of 0.75 mg/kg BW of dexamethasone and oral administration of 2, 6, and 12 mg/kg BW of astaxanthin, respectively. All experimental animals were administered therapy for 10 days. Hematological profiles were evaluated using a blood analyzer, whereas IL-6 and TNF-α expression was evaluated using immunohistochemical staining. Results: Based on leukocyte, erythrocyte, hemoglobin, and hematocrit characteristics, groups T2 and T3 were generally found to be significantly different ( Conclusion: The administration of 12 mg/kg BW of astaxanthin may be an antidote to dexamethasone toxicity in albino rats, according to the overall assessment of the hematological profile, IL-6, and TNF-α cytokines in the kidney.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.